Chinese Coptionnical Trial Register (ChiCTR) - The world health organization international coptionnical trials registered organization registered platform

简体中文|English

Trial search

Nation, Province(City)

Measure

Ethical committee

Study type

Trial search

reset

Public title

Scientific title

Subject ID

Registration Status

Registration number

Secondary ID

Applicant

Study leader

Year

Primary sponsor

Secondary sponsor

Source(s) of funding

Target disease

Target disease code

Study type

Study phase

Study design

Recruiting status

Execute time(From)

Execute time(END)

Sign the informed consent

Gender

Nation(Area)

Province

City

Unit (hospital)

Institution

Level of the institution

Intervention

Intervention code

Approved by ethic committee

Calculated Results after the Study Completed puboptionc access

5 trials have been registered

Historical versions	Registration number	Public title	Type	Registration time
Historical Versions	ChiCTR2500115697	The efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in resectable elderly NSCLC patients with stage IIA-IIIB The First Medical Center of Chinese PLA General Hospital	Observational study	2025/12/30
Historical Versions	ChiCTR2500107375	Differential expression analysis of tumor-infiltrating lymphocytes (TILs) and its safety in the treatment of intermediate and advanced non-small cell lung cancer The Fourth Hospital of Hebei Medical University	Interventional study	2025/08/11
Historical Versions	ChiCTR2500103374	Firmonertinib as adjuvant therapy for completely resected stage IA2-IB EGFR mutation-positive NSCLC patients with high-risk factors:a real-world study The Fourth Hospital of Hebei Medical University	Observational study	2025/05/28
Historical Versions	ChiCTR2500099395	160mg furmonertinib for the first-line treatment of EGFR-sensitive mutations NSCLC with BM/LM : a single-arm, prospective clinical study The Fourth Hospital of Hebei Medical University	Interventional study	2025/03/24
Historical Versions	ChiCTR2500096734	A real-world study of vormetinib in patients with EGFR mutation-positive NSCLC who relapsed after adjuvant therapy with the first generation EGFR-TKI after radical surgery The Forthe Hospital of Hebei Medical University	Interventional study	2025/02/05

Chinese Clinical Trial Registry, Primary Registry of WHO International Clinical Trials Registry Platform

蜀ICP备16010396号-9

Note: It is recommended to use the widescreen display resolution of Internet Explorer 8.0 or later